1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Abbisko And Merck KGaA MANEUVER Pimicotinib Towards Approval

 
• By Elizabeth Cairns

Pimicotinib’s Phase III data in tenosynovial giant cell tumor are better than its rivals but the fight for a small number of patients will be fierce.

Conceptual image of increasing value of money shown by a coin from small to large number

Following a couple of fairly disastrous trial failures, Merck KGaA can finally celebrate a hit. The colony stimulating factor-1 (CSF-1) inhibitor pimicotinib, originated by China-based Abbisko and licensed to the German group, has shown an impressive response rate in its pivotal trial in tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm of the joints.

Key Takeaways
  • Abbisko’s colony stimulating factor-1 inhibitor pimicotinib, licensed to Merck KGaA in China, has hit in Phase III.
  • The response rate looks better...

Pimicotinib’s response rate in the MANEUVER trial compares well with the only approved product for this disease, Daiichi Sankyo’s Turalio (pexidartinib). But TGCT is a tiny indication, and yet another...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

More from Anticancer

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 
• By Alaric DeArment

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.